Fibcd1 to Treat or Prevent Muscle Wasting (SJ-20-0008)

St. Jude Reference #SJ-20-0008

Description

While there are many physical therapies and exercises to help rebuild muscle, there is no clinical therapeutic for prevention of skeletal muscle wasting. Researchers at St. Jude searching for solutions to this unmet need found that a recombinant protein Fibcd1 (recombinant Fibrinogen C Domain Containing 1) variant rescues the decrease in muscle cell size (myofiber atrophy) that is a feature of many human disease conditions, such as cancer, aging, diabetes, neurological disorders, infections, bed rest or cast immobilized limb, corticosteroid or other drug use, and others; and a worsening factor for prognosis.

Their proposed invention is a systemic or local injection of human rFibcd1 used to rescue and/or prevent the loss of muscle mass (muscle wasting) that occurs due to myofiber atrophy with many disease conditions. 


Keywords

Muscle wasting due to cancer, aging, diabetes, neurological disorders, infections, bed ridden


Granted Patents or Published Applications

Application filed, available under confidentiality.


Related Scientific References

Waiting on publication.


Licensing Opportunities

We are seeking partners to develop systemic rFibcd1 injection, or localized injection to preserve the mass and function of key muscles (such as the diaphragm, which is needed for breathing), to promote the maintenance of the mass of muscles in a cast-immobilized limb, or etc. Contact: chad.riggs@stjude.org

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.